

Transforming Healthcare. Transforming Lives.



Fact Sheet

Enabling Equitable Access to Biosimilars

Biocon Biologics is a unique, fully integrated global biosimilars company committed to transforming healthcare by enabling affordable access to high quality biosimilars for millions of patients worldwide.

Its expertise in developing, manufacturing, distributing and commercializing biosimilars has made Biocon Biologics a frontrunner in biosimilars, which are follow-on biologics typically launched after originator molecules lose patent protection. The Company has commercialized nine biosimilars from its portfolio which are addressing the patients' needs in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan.

With a unique portfolio of insulins, monoclonal antibodies, and conjugated recombinant proteins to treat an array of non-communicable diseases such as diabetes, cancer, autoimmune diseases, serious eye conditions and bone-related disorders, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access.



BIOSIMILARS FRONTRUNNER

Biocon Biologics has demonstrated success with a proven track record of multiple successful biosimilar approvals, including several global 'firsts.' The Company received the industry's first approval of an interchangeable biosimilar for Insulin Glargine in the U.S. It is also the first globally to receive approvals for biosimilar Trastuzumab, biosimilar Pegfilgrastim, interchangeable biosimilar Aflibercept from the U.S. Food and Drug Administration (FDA).



GLOBAL SCALE MANUFACTURING

The Company has invested in commercial scale, globally compliant manufacturing facilities with integrated capabilities across drug substance, drug product and devices. It ranks among the world's Top 15 biomanufacturing companies in terms of capacity and is among the Top 3 global players in rh-Insulin and Insulin Glargine.

The Company upholds the highest standards of product quality and efficacy, underlining its unwavering commitment to the safety of patients. It has obtained 90+ cGMP approvals from international regulatory agencies.



WORLDWIDE COMMERCIAL CAPABILITIES

Biocon Biologics has a commercial presence in 120+ countries through self-led, partner-led and hybrid business models. The Company has customer-facing commercial capabilities and related infrastructure in several markets worldwide such as the U.S., Canada, and 19 European countries, including the Top 5 markets of UK, Germany, France, Spain and Italy. It has commercial reach across 80+ Emerging Markets, of which it has direct commercial presence in 8 countries.

BIOCON BIOLOGICS: QUICK FACTS



Bengaluru, India



Employees : 5,000+

FY2025 REVENUE



Revenue : INR 90,174 million (\$1.1 bn)

BIOSIMILARS GLOBAL PORTFOLIO: 20

COMMERCIALIZED GLOBALLY: 9

Ogivri (Trastuzumab)

Fulphila (Pegfilgrastim)

Abevmy (Bevacizumab)

Hulio (Adalimumab*)

Nepexto (Etanercept*)

Yesintek™ (Ustekinumab)

Semglee (Glargine U100)

Kirsty (Aspart)

Insugen (rh-Insulin)

Commercial reach: 120+ countries

Patients served globally: 5.8+ mn / year

R&D sites: 2 (Bengaluru, Chennai)

Strong scientific talent and state-of-the-art R&D infrastructure

Bio-Manufacturing Capacity:
Among Top 15 globally

Manufacturing sites: 3
(2 in Bengaluru, India; 1 in Johor, Malaysia)

Drug substance, drug product & devices
manufacturing capabilities for insulins, mAbs

cGMP approvals received: 90+

*In-licensed products

By addressing healthcare affordability and access, Biocon Biologics is easing the financial burden for patients, governments and healthcare systems, and enabling global health equity.

PROMISING PIPELINE

Biocon Biologics, which invests in biosimilars with the singular purpose of broadening access to biologic therapies for many life-threatening conditions, has a pipeline of several biosimilar assets.

| Therapy Area | Oncology | Immunology | Diabetes | Bone Health | Others |
|---------------|---------------------------|----------------------|---------------------------------------|-------------|---------------------|
| Late Stage* | bDenosumab bPertuzumab | | | bDenosumab | |
| Early Stage** | 2 Undisclosed Assets | 3 Undisclosed Assets | bGlargine U300 1 Undisclosed Asset | | 1 Undisclosed Asset |

*Phase III to regulatory submissions **Pre-clinical stage

STRONG ESG FOCUS

The Company's business practices align with the broader objective of empowering the global community to achieve the UN Sustainable Development Goals. Biocon Biologics achieved an ESG score of 53 in the first year of participating independently in the S&P Global Corporate Sustainability Assessment. Based on the ESG score, the Company debuted in the Sustainability Yearbook 2025 as an independent member.

Executive Committee

Shreehas Tambe
CEO & Managing Director

Kedar Upadhye
Chief Financial Officer

Rhonda Duffy
Chief Operating Officer

Matthew Erick
Chief Commercial Officer -
Advanced Markets

Susheel Umesh
Chief Commercial Officer -
Emerging Markets

Anuj Goel
Chief Development Officer

Naveen Narayanan
Global Head of HR

Our extended Global Reach

120+ Countries



Biocon Biologics Limited

Biocon House, Semicon Park, Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560 100. India. T: +91 80 6775 6775

For more information:

Seema Ahuja

Global Head of Corporate Brand
& Head of Communications - EMs,

Biocon Biologics

Email: Group.Communications@biocon.com

Website: www.bioconbiologics.com

Follow us at : 

Note: The information in this Fact Sheet is given as of the date mentioned, and Biocon Biologics does not assume any obligation to update the information on a frequent basis.

Last Updated: June 2025